AU2002319296A1 - Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes - Google Patents

Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes

Info

Publication number: AU2002319296A1
Authority: AU; Australia
Prior art keywords: alkoxyphenyl; treatment; diseases associated; regulated processes; substituted imidazotriazinones
Prior art date: 2001-07-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002319296A

Other versions

AU2002319296B2 (en

Inventor

Tiemo-Joerg Bandel

Wolfgang Barth

Erwin Bischoff

Helmut Haning

Ulrich Niewohner

Afssaneh Rahbar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Schering Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-23

Filing date

2002-07-17

Publication date

2003-05-29

2001-07-23 Priority claimed from DE10135815A external-priority patent/DE10135815A1/en

2002-07-17 Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG

2003-05-29 Publication of AU2002319296A1 publication Critical patent/AU2002319296A1/en

2007-08-30 Application granted granted Critical

2007-08-30 Publication of AU2002319296B2 publication Critical patent/AU2002319296B2/en

2009-05-14 Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Request for Assignment Assignors: BAYER HEALTHCARE AG

2022-07-17 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10135815A DE10135815A1 (en)	2001-07-23	2001-07-23	Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
DE10135815.6		2001-07-23
PCT/EP2002/007959 WO2003011262A2 (en)	2001-07-23	2002-07-17	Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes

Publications (2)

Publication Number	Publication Date
AU2002319296A1 true AU2002319296A1 (en)	2003-05-29
AU2002319296B2 AU2002319296B2 (en)	2007-08-30

Family

ID=7692784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002319296A Ceased AU2002319296B2 (en)	2001-07-23	2002-07-17	Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cGMP regulated processes

Country Status (28)

Country	Link
US (3)	US6930108B2 (en)
EP (2)	EP1733728A3 (en)
JP (1)	JP2005504751A (en)
KR (1)	KR20040032865A (en)
CN (1)	CN1649593A (en)
AT (1)	ATE442144T1 (en)
AU (1)	AU2002319296B2 (en)
BG (1)	BG108533A (en)
BR (1)	BR0211359A (en)
CA (1)	CA2454414A1 (en)
CO (1)	CO5560536A2 (en)
CZ (1)	CZ2004128A3 (en)
DE (2)	DE10135815A1 (en)
EC (1)	ECSP044956A (en)
EE (1)	EE200400056A (en)
ES (1)	ES2330418T3 (en)
HR (1)	HRP20040065A2 (en)
HU (1)	HUP0500734A3 (en)
IL (1)	IL159840A0 (en)
MA (1)	MA26128A1 (en)
MX (1)	MXPA04000675A (en)
NO (1)	NO20040294L (en)
NZ (1)	NZ530703A (en)
PL (1)	PL373392A1 (en)
RU (1)	RU2321406C9 (en)
SK (1)	SK442004A3 (en)
UA (1)	UA76997C2 (en)
WO (1)	WO2003011262A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (en) *	2001-07-23	2003-02-06	Bayer Ag	Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
JP2006219374A (en) *	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Imidazotriazinone derivatives having PDE7 inhibitory action
DE102004023069A1 (en)	2004-05-11	2005-12-08	Bayer Healthcare Ag	New dosage forms of the PDE 5 inhibitor vardenafil
DE102004038328A1 (en) *	2004-08-06	2006-03-16	Bayer Healthcare Ag	New uses of 2-phenyl-substituted imidazotriazinone derivatives
NZ561746A (en)	2005-04-19	2011-09-30	Nycomed Gmbh	Roflumilast for the treatment of pulmonary hypertension
EP2521721B1 (en)	2009-12-30	2014-10-01	Shanghai Fochon Pharmaceutical Co. Ltd	3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
AT512084A1 (en) *	2011-10-20	2013-05-15	Univ Wien Tech	DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
EP3082428A4 (en)	2013-12-09	2017-08-02	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
RU2753056C2 (en) *	2016-12-16	2021-08-11	Систик Файбросис Фаундейшн	Bicyclic heteroaryl derivatives as cftr stimulators
CN113583003A (en) *	2021-08-05	2021-11-02	广东西捷药业有限公司	Vardenafil analogue and synthetic method and application thereof
CN113461694A (en) *	2021-08-05	2021-10-01	广东西捷药业有限公司	Vardenafil analogue and synthetic method and application thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE791025A (en)	1971-11-19	1973-05-07	Allen & Hanburys Ltd	HETEROCYCLIC COMPOUNDS
GB1457873A (en)	1973-01-04	1976-12-08	Allen & Hanburys Ltd	Imidazotriazines
DK109578A (en)	1977-03-25	1978-09-26	Allen & Hanburys Ltd	PROCEDURE FOR MAKING HETEROCYCLIC COMPOUNDS
US4308384A (en)	1978-09-18	1981-12-29	Glaxo Group Limited	Production of triazinones
US4479210A (en) *	1982-11-19	1984-10-23	U.S. Philips Corporation	Record-disc player
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
PH31245A (en) *	1991-10-30	1998-06-18	Janssen Pharmaceutica Nv	1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5602110A (en) *	1994-08-31	1997-02-11	Case Western Reserve University	Method and composition for treating cystic fibrosis
US5656629A (en) *	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
KR100430059B1 (en) *	1995-04-10	2004-09-24	후지사와 야꾸힝 고교 가부시키가이샤	Indole derivatives as cGMP-PDE inhibitors
AU722514B2 (en) *	1995-12-28	2000-08-03	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
CA2238283C (en) *	1997-05-30	2002-08-20	Cell Pathways, Inc.	Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
CA2309332C (en) *	1997-11-12	2002-12-03	Bayer Aktiengesellschaft	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19812462A1 (en) *	1998-03-23	1999-09-30	Bayer Ag	New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases
CN100436418C (en) *	1997-12-12	2008-11-26	Osi制药公司	N-benzyl-3-indenylacetamide derivatives for the treatment of tumors
US6087368A (en) *	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (en)	1998-06-20	1999-12-23	Bayer Ag	New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
IL132406A0 (en) *	1998-10-21	2001-03-19	Pfizer Prod Inc	Treatment of bph with cgmp elevators
US6225315B1 (en) *	1998-11-30	2001-05-01	Pfizer Inc	Method of treating nitrate-induced tolerance
FR2792634B1 (en) *	1999-04-20	2001-06-01	Synthelabo	2-ALCOXY-CYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
IL130968A (en) *	1999-07-15	2002-12-01	Shmuel Simon	Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
WO2001032170A1 (en) *	1999-09-13	2001-05-10	Swope David M	Composition and method for decreasing neurologic symptomatology
DE19943815A1 (en) *	1999-09-14	2001-03-15	Merck Patent Gmbh	Use of thienopyrimidines
TWI265925B (en) *	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2323008C (en)	1999-10-11	2005-07-12	Pfizer Inc.	Pharmaceutically active compounds
ATE341329T1 (en) *	1999-10-12	2006-10-15	Lilly Icos Llc	MEDICINAL PRODUCTS FOR THE TREATMENT OF NEUROPATHIES
IL152925A (en) *	1999-10-21	2010-04-15	Pfizer	Pharmaceutical compositions for treatment of neuropathy comprising an inhibitor of cyclic guanosine 3',5'-monophosphate phosphodiesterase 5 and either gabapentin or pregabalin
TWI224966B (en) *	1999-11-02	2004-12-11	Pfizer	Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
GB0008694D0 (en) *	2000-04-07	2000-05-31	Novartis Ag	Organic compounds
CA2407031A1 (en) *	2000-04-19	2001-10-25	Lilly Icos Llc	Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
EP1365806A2 (en) *	2000-04-19	2003-12-03	Johns Hopkins University	Use of no acttivators for treatment and prevention of gastrointestinal disorders
CN1446084A (en) *	2000-08-11	2003-10-01	辉瑞大药厂	Treatment of insulin resistance syndrome
JP2004507514A (en) *	2000-08-30	2004-03-11	リリー　アイコス　リミテッド　ライアビリティ　カンパニー	Migraine treatment
GB0025782D0 (en) *	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
EP1355651A2 (en) *	2001-02-02	2003-10-29	Pfizer Limited	Treatment of diabetes mellitus using vardenafil
DE10107639A1 (en) *	2001-02-15	2002-08-22	Bayer Ag	2-alkoxyphenyl substituted imidazotriazinones
WO2002089808A1 (en) *	2001-05-09	2002-11-14	Bayer Healthcare Ag	Novel use of 2-phenyl-substituted imidazotriazinones
DE10135815A1 (en) *	2001-07-23	2003-02-06	Bayer Ag	Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
GB0129274D0 (en) *	2001-12-06	2002-01-23	Pfizer Ltd	Novel kit
JP2005527510A (en) *	2002-03-06	2005-09-15	セレジーファーマシューティカルズインコーポレーティッド	Formulations and methods for using nitric oxide mimetics in the treatment of cancer

2001
- 2001-07-23 DE DE10135815A patent/DE10135815A1/en not_active Withdrawn
2002
- 2002-07-17 JP JP2003516493A patent/JP2005504751A/en active Pending
- 2002-07-17 ES ES02748858T patent/ES2330418T3/en not_active Expired - Lifetime
- 2002-07-17 RU RU2004105265/15A patent/RU2321406C9/en not_active IP Right Cessation
- 2002-07-17 EP EP06017257A patent/EP1733728A3/en not_active Withdrawn
- 2002-07-17 CN CNA028144759A patent/CN1649593A/en active Pending
- 2002-07-17 UA UA2004021279A patent/UA76997C2/en unknown
- 2002-07-17 MX MXPA04000675A patent/MXPA04000675A/en active IP Right Grant
- 2002-07-17 HU HU0500734A patent/HUP0500734A3/en unknown
- 2002-07-17 EE EEP200400056A patent/EE200400056A/en unknown
- 2002-07-17 CZ CZ2004128A patent/CZ2004128A3/en unknown
- 2002-07-17 US US10/483,462 patent/US6930108B2/en not_active Expired - Fee Related
- 2002-07-17 WO PCT/EP2002/007959 patent/WO2003011262A2/en not_active Ceased
- 2002-07-17 KR KR10-2004-7001050A patent/KR20040032865A/en not_active Ceased
- 2002-07-17 BR BR0211359-7A patent/BR0211359A/en not_active IP Right Cessation
- 2002-07-17 PL PL02373392A patent/PL373392A1/en not_active Application Discontinuation
- 2002-07-17 IL IL15984002A patent/IL159840A0/en unknown
- 2002-07-17 CA CA002454414A patent/CA2454414A1/en not_active Abandoned
- 2002-07-17 EP EP02748858A patent/EP1474150B1/en not_active Expired - Lifetime
- 2002-07-17 NZ NZ530703A patent/NZ530703A/en unknown
- 2002-07-17 AT AT02748858T patent/ATE442144T1/en not_active IP Right Cessation
- 2002-07-17 SK SK44-2004A patent/SK442004A3/en not_active Application Discontinuation
- 2002-07-17 DE DE50213840T patent/DE50213840D1/en not_active Expired - Fee Related
- 2002-07-17 AU AU2002319296A patent/AU2002319296B2/en not_active Ceased
- 2002-07-17 HR HRP20040065 patent/HRP20040065A2/en not_active Application Discontinuation
2004
- 2004-01-14 BG BG108533A patent/BG108533A/en unknown
- 2004-01-19 EC EC2004004956A patent/ECSP044956A/en unknown
- 2004-01-22 NO NO20040294A patent/NO20040294L/en not_active Application Discontinuation
- 2004-01-22 MA MA27497A patent/MA26128A1/en unknown
- 2004-02-23 CO CO04015666A patent/CO5560536A2/en not_active Application Discontinuation
2005
- 2005-06-17 US US11/156,082 patent/US7276504B2/en not_active Expired - Fee Related
2007
- 2007-10-01 US US11/906,382 patent/US20080085897A1/en not_active Abandoned

Publication	Publication Date	Title
AU2003286567A1 (en)	2004-05-13	Methods for the treatment of skin disorders
AU2003291992A1 (en)	2004-05-25	Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003279338A1 (en)	2004-05-25	Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003285091A1 (en)	2004-06-07	Interferon antagonists useful for the treatment of interferon related diseases
AU2002332430A1 (en)	2003-02-17	Methods of treating neuropilin-mediated diseases
AU2002334870B8 (en)	2003-04-22	Combinations for the treatment of immunoinflammatory disorders
AU2003228819A1 (en)	2003-11-17	Combinations for the treatment of inflammatory skin disorders
AU2002210385A1 (en)	2002-04-29	Furazanyl-triazole derivates for the treatment of diseases
AU2003258145A1 (en)	2004-02-25	Substituted phenylindoles for the treatment of hiv
AU2002319296A1 (en)	2003-05-29	Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003303217A1 (en)	2004-07-14	Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003270683A1 (en)	2004-04-08	Compounds for the treatment of premature ejaculation
AU2002359635A1 (en)	2003-06-17	Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU2002365621A1 (en)	2003-06-17	Composition for treating the surface of the skin
GB0201025D0 (en)	2002-03-06	The treatment of degenerative diseases
AU2003236787A1 (en)	2003-09-18	Use of alkylphosphocholines for the preventative treatment of protozoan diseases
AU2003259689A1 (en)	2004-02-25	3-imino-2-indolones for the treatment of depression and/or anxiety
AU2002344959A1 (en)	2003-11-17	Use of fasl for the treatment of neurodegenerative diseases
AU2001274446A1 (en)	2001-12-17	Vip-related peptides for the treatment of skin disorders
AU2002365654A1 (en)	2003-06-17	Treatment of diseases via the skin
AU2002357964A1 (en)	2003-07-09	Use of coagulant-active antitrhombin iii for the therapy of angiogenesis-dependent diseases
AU2002350513A1 (en)	2003-04-22	Use of solasonine for the treatment of skin tumors
HK1073262A (en)	2005-09-30	Pyranoindazoles and their use for the treatment of glaucoma
GB0108892D0 (en)	2001-05-30	The treatment of respiratory diseases